Anthropic's path to Wall Street has a name now: ANT, the ticker under which the AI lab's shares will trade on the Nasdaq Global Select Market once its public filing clears regulatory review. The S-1 registration became public in late October, turning months of reported back-channel conversations about an eventual listing into an actual, numbered document that outside analysts can finally pick apart instead of speculating about from leaked fragments and anonymous sourcing.
The valuation conversation attached to that filing has moved in a direction that would have seemed implausible even a year ago. Anthropic's last private funding round, a $65 billion raise completed in May, valued the company at roughly $965 billion. Reported discussions ahead of the public listing have floated figures approaching $2 trillion, alongside a potential capital raise of up to $100 billion, though people close to the process have cautioned that those numbers remain preliminary and could shift materially once institutional investors actually begin pricing the deal in earnest.
Timing has already proven harder to pin down than the company's early guidance suggested. An October listing was the original target, pushed back as broader market caution around AI valuations crept into investor sentiment following a string of warnings about overextended infrastructure spending across the sector. The current expectation inside the process points to a listing during the week of 16 November, though anyone who has followed this filing closely knows that date has already moved once and could move again before the actual bell rings.
What makes this listing different from a typical tech IPO is the scrutiny Anthropic invites simply by being what it is: a frontier AI lab whose core product is also the subject of an active global safety and regulation debate. The risk-factor section of the S-1 carries legal weight well beyond boilerplate, forcing the company to put on the public record exactly how it thinks about the risks its own technology poses, in language that will be quoted back at it by regulators, competitors and plaintiffs' lawyers for years regardless of how the stock performs.
For a market that has watched AI valuations swing from euphoria to nervousness and back again within the space of a single year, Anthropic's listing will function as something closer to a referendum than a routine capital-markets event. A successful debut at anything close to the reported figures would validate the industry's most bullish believers. A disappointing one would hand considerable ammunition to the growing chorus of voices warning that AI valuations have detached from anything resembling fundamentals, and either outcome will ripple well beyond one company's cap table.